W

Windward Bio WWB

$22.64
−12.11%
yesterday

Posts

About Windward Bio Group AG Common Shares

Windward Bio is a Swiss clinical-stage biotech developing ultra-long-acting antibody medicines for asthma, COPD and atopic dermatitis. Its lead candidates, WIN378 and WIN027, block the TSLP and IL-13 pathways and are built for dosing about twice a year. It has no products on sale and no revenue, and it funds its trials with money raised from investors, including its November 2026 IPO.